60 Degrees Pharmaceuticals (SXTP) Q1 2024 Annual Earnings
SXTP·Reported May 15, 2024·Before market open
60 Degrees Pharmaceuticals reported Q1 2024 revenue of $105.7K, missed analyst consensus of $134.5K by $28.8K. Diluted EPS came in at $1.80, beat the $-9.60 consensus by $11.40.
Revenue
$105.7Kmissed by $28.8K
Consensus: $134.5KDiluted EPS
$1.80beat by $11.40
Consensus: $-9.60
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about 60 Degrees Pharmaceuticals's Q1 2024 earnings report.
60 Degrees Pharmaceuticals (SXTP) reported Q1 2024 earnings on May 15, 2024 before market open.
60 Degrees Pharmaceuticals reported revenue of $105.7K and diluted EPS of $1.80 for Q1 2024.
Revenue missed the consensus estimate of $134.5K by $28.8K. EPS beat the consensus estimate of $-9.60 by $11.40.
You can read the 10-K periodic report (0001213900-24-028577) directly on SEC EDGAR. The filing index links above go to sec.gov.